Beverly Hills Private Wealth LLC Decreases Stock Holdings in AstraZeneca PLC $AZN

Beverly Hills Private Wealth LLC reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 10.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 6,089 shares of the company’s stock after selling 679 shares during the period. Beverly Hills Private Wealth LLC’s holdings in AstraZeneca were worth $426,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Lindbrook Capital LLC lifted its position in shares of AstraZeneca by 1.9% during the 1st quarter. Lindbrook Capital LLC now owns 7,574 shares of the company’s stock worth $557,000 after purchasing an additional 141 shares during the last quarter. Principal Securities Inc. lifted its position in shares of AstraZeneca by 0.5% during the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company’s stock worth $2,062,000 after purchasing an additional 142 shares during the last quarter. Sage Mountain Advisors LLC lifted its position in shares of AstraZeneca by 3.4% during the 1st quarter. Sage Mountain Advisors LLC now owns 4,478 shares of the company’s stock worth $329,000 after purchasing an additional 147 shares during the last quarter. Richardson Financial Services Inc. lifted its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after purchasing an additional 149 shares during the last quarter. Finally, Evergreen Capital Management LLC raised its stake in AstraZeneca by 0.7% during the 1st quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock worth $1,743,000 after acquiring an additional 155 shares in the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on AZN. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Trading Down 1.0%

NASDAQ AZN opened at $83.87 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The firm has a market cap of $260.11 billion, a PE ratio of 31.53, a P/E/G ratio of 1.56 and a beta of 0.36. AstraZeneca PLC has a one year low of $61.24 and a one year high of $86.57. The firm’s fifty day moving average is $80.42 and its two-hundred day moving average is $73.97.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.24 earnings per share. Analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were issued a $0.505 dividend. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s payout ratio is presently 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.